Literature DB >> 9596241

Potential and limitations of echocontrast-enhanced ultrasonography in acute stroke patients: a pilot study.

D G Nabavi1, D W Droste, V Kemény, G Schulte-Altedorneburg, S Weber, E B Ringelstein.   

Abstract

BACKGROUND AND
PURPOSE: Ultrasonography (US) is a well-established method used to assess the brain-supplying arteries in the acute stroke setting. However, several technical and anatomic limitations are known to reduce its diagnostic accuracy and confidence level. Echocontrast agents (ECA) are known to improve the signal-to-noise ratio by enhancing the intensity of the reflecting Doppler signal. We undertook this prospective study to evaluate the diagnostic value of ECA in a consecutive, nonselected cohort of acute stroke patients with insufficient native US investigations.
METHODS: During a 1-year period, 25 patients were examined within 48 hours of the onset of stroke. The need for ECA was due to an insufficient transtemporal (n=18), transforaminal (n=4), or extracranial (n=3) imaging of arteries potentially involved in the ischemic event. In 12 patients, a diagnostic suspicion could natively be raised, whereas in the other 13 patients, the strongly reduced image quality did not allow for any neurovascular conclusions. Four grams of Levovist was injected at a concentration of 200 mg/mL and 400 mg/mL for the extracranial and transcranial insonations, respectively. The effect of the echocontrast enhancement was assessed with respect to (1) signal enhancement, (2) image quality, (3) final diagnostic confidence, and (4) the need for additional neurovascular imaging methods.
RESULTS: In all but one patient (96%), a strong signal enhancement was noted, leading to a moderate (n=11) or strong improvement (n=10) of the transcranial image quality. Thus in a total of 18 patients (72%), the echoenhancement provided a neurovascular diagnosis of sufficient confidence. This led to the confirmation of the previously suspected findings and disclosed three further occlusions and four stenoses of the intracranial arteries. In contrast, for the three extracranial examinations the image quality was not sufficiently improved because of persistent color artifacts derived from adjacent neck vessels. Besides the seven patients with inconclusive examinations, five patients with conclusive echoenhanced US studies (48% in total) demanded additive neurovascular imaging studies, based on the clinical decision of the attending physicians. This led to confirmation of all high-confident sonographic diagnoses.
CONCLUSIONS: In summary, in approximately three fourths of our acute stroke patients with insufficient native US investigations, echocontrast enhancement enabled a reliable neurovascular diagnosis, allowing the cancellation of additive neurovascular imaging procedures in half of our cohort. Our preliminary results suggest that ECA can reasonably support the early cerebrovascular workup in the acute stroke setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596241     DOI: 10.1161/01.str.29.5.949

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  10 in total

1.  Vertebrobasilar transcranial color-coded duplex ultrasonography: improvement with echo enhancement.

Authors:  Erwin Stolz; Martin Nückel; Irene Mendes; Tibo Gerriets; Manfred Kaps
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

2.  Echo-enhanced transcranial color-coded duplex sonography in the diagnosis of cerebrovascular events: a validation study.

Authors:  A Kunz; G Hahn; D Mucha; A Müller; K M Barrett; R von Kummer; G Gahn
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

3.  Contrast-enhanced three-dimensional transcranial color-coded sonography of intracranial stenoses.

Authors:  Christof Klötzsch; Alessandro Bozzato; Gero Lammers; Michael Mull; Johannes Noth
Journal:  AJNR Am J Neuroradiol       Date:  2002-02       Impact factor: 3.825

4.  Contrast-enhanced transcranial color-coded duplexsonography in stroke patients with limited bone windows.

Authors:  G Gahn; J Gerber; S Hallmeyer; G Hahn; R H Ackerman; H Reichmann; R von Kummer
Journal:  AJNR Am J Neuroradiol       Date:  2000-03       Impact factor: 3.825

5.  Relationship between findings of conventional and contrast-enhanced transcranial color-coded real-time sonography and angiography in patients with basilar artery occlusion.

Authors:  Masatoshi Koga; Kazumi Kimura; Kazuo Minematsu; Takenori Yamaguchi
Journal:  AJNR Am J Neuroradiol       Date:  2002-04       Impact factor: 3.825

6.  The effect of contrast material on transcranial Doppler evaluation of normal middle cerebral artery peak systolic velocity.

Authors:  H G Khan; P Gailloud; R O Bude; J B Martin; K T Szopinski; C Khaw; D A Rüfenacht; K J Murphy
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

7.  Real-time cerebral angiography: sensitivity of a new contrast-specific ultrasound technique.

Authors:  T Hölscher; J A Sattin; R Raman; W Wilkening; C V Fanale; S E Olson; R F Mattrey; P D Lyden
Journal:  AJNR Am J Neuroradiol       Date:  2007-04       Impact factor: 3.825

8.  Multimodal neurophysiological and psychometric evaluation among patients with systemic lupus erythematosus.

Authors:  Ghaydaa A Shehata; Yasser Mb Elserogy; Hossam Eddin K Ahmad; Mohamed I Abdel-Kareem; Ashraf M Al-Kabeer; Mohamed M Rayan; Mohamed Es Abd El-Baky
Journal:  Int J Gen Med       Date:  2011-04-20

9.  Subclinical cerebrovascular cognitive function, and mood changes in patients with systemic lupus erythematosus.

Authors:  Ghaydaa A Shehata; Mohamed I Abdel-Kareem; Abd Ellah N Yassin; Abdel Hamid R El Adl
Journal:  Open Access Rheumatol       Date:  2010-07-03

10.  Perfusion CT in acute stroke: prediction of vessel recanalization and clinical outcome in intravenous thrombolytic therapy.

Authors:  Stephan P Kloska; Ralf Dittrich; Tobias Fischer; Darius G Nabavi; Roman Fischbach; Peter Seidensticker; Nani Osada; E Bernd Ringelstein; Walter Heindel
Journal:  Eur Radiol       Date:  2007-06-05       Impact factor: 7.034

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.